Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

PURPOSE: Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Stroes, Charlotte I., Schokker, Sandor, Creemers, Aafke, Molenaar, Remco J., Hulshof, Maarten C.C.M., van der Woude, Stephanie O., Bennink, Roel J., Mathôt, Ron A.A., Krishnadath, Kausilia K., Punt, Cornelis J.A., Verhoeven, Rob H.A., van Oijen, Martijn G.H., Creemers, Geert-Jan, Nieuwenhuijzen, Grard A.P., van der Sangen, Maurice J.C., Beerepoot, Laurens V., Heisterkamp, Joos, Los, Maartje, Slingerland, Marije, Cats, Annemieke, Hospers, Geke A.P., Bijlsma, Maarten F., van Berge Henegouwen, Mark I., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007286/
https://ncbi.nlm.nih.gov/pubmed/31809243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01814
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares